STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe

dc.contributor.authorMelanie Grehn
dc.contributor.authorAlcántara Carrió, María Del Pino
dc.contributor.authorJoost J C Verhoeff
dc.date.accessioned2024-02-08T09:19:05Z
dc.date.available2024-02-08T09:19:05Z
dc.date.issued2023-03-06
dc.description.abstractThe EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions’ experience in VT catheter ablation (83% ≥ 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.
dc.description.departmentDepto. de Radiología, Rehabilitación y Fisioterapia
dc.description.facultyFac. de Medicina
dc.description.facultyUniversidad Complutense de Madrid
dc.description.refereedTRUE
dc.description.sponsorshipUnión Europea
dc.description.statuspub
dc.identifier.citationGrehn M, Mandija S, Miszczyk M, Krug D, Tomasik B, Stickney KE, Alcantara P, Alongi F, Anselmino M, Aranda RS, Balgobind BV, Boda-Heggemann J, Boldt LH, Bottoni N, Cvek J, Elicin O, De Ferrari GM, Hassink RJ, Hazelaar C, Hindricks G, Hurkmans C, Iotti C, Jadczyk T, Jiravsky O, Jumeau R, Kristiansen SB, Levis M, López MA, Martí-Almor J, Mehrhof F, Møller DS, Molon G, Ouss A, Peichl P, Plasek J, Postema PG, Quesada A, Reichlin T, Rordorf R, Rudic B, Saguner AM, Ter Bekke RMA, Torrecilla JL, Troost EGC, Vitolo V, Andratschke N, Zeppenfeld K, Blamek S, Fast M, de Panfilis L, Blanck O, Pruvot E, Verhoeff JJC. STereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe. Europace. 2023 Apr 15;25(4):1284-1295. doi: 10.1093/europace/euac238. PMID: 36879464; PMCID: PMC10105846.
dc.identifier.doi10.1093/europace/euac238
dc.identifier.issn1099-5129
dc.identifier.issn1532-2092
dc.identifier.officialurlhttps://academic.oup.com/europace/article/25/4/1284/7069964?login=true
dc.identifier.pmid36879464
dc.identifier.relatedurlhttps://pubmed.ncbi.nlm.nih.gov/36879464/
dc.identifier.urihttps://hdl.handle.net/20.500.14352/100230
dc.issue.number4
dc.journal.titleEuropace
dc.language.isoeng
dc.page.final1295
dc.page.initial1284
dc.publisherOxford University Press on behalf of the European Society of Cardiology.
dc.relation.projectIDHorizon-2020 No. 945119.
dc.rightsAttribution-NonCommercial 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subject.cdu615.849.1
dc.subject.keywordCardiac arrhythmias
dc.subject.keywordConsortium
dc.subject.keywordEU Horizon 2020
dc.subject.keywordStereotactic arrhythmia radioablation
dc.subject.keywordStereotactic body radiotherapy
dc.subject.keywordVentricular tachycardia
dc.subject.ucmCiencias Biomédicas
dc.subject.unesco32 Ciencias Médicas
dc.titleSTereotactic Arrhythmia Radioablation (STAR): the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number25
dspace.entity.typePublication
relation.isAuthorOfPublicationd57a2409-23f5-41af-b8b9-680c861e9502
relation.isAuthorOfPublication.latestForDiscoveryd57a2409-23f5-41af-b8b9-680c861e9502

Download

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
STereotactic Arrhythmia Radioablation (STAR) and review of current patterns of STAR practice in Europe.pdf
Size:
5.54 MB
Format:
Adobe Portable Document Format

Collections